pLOG

2025-01-08

2024 PatientsForce Patient Assistance Service Report

 

Journey Management Focused on Patient Outcome Value

Value-Based Healthcare, aiming at patient treatment outcomes, is the core service philosophy of PatientsForce. The PatientsForce team is committed to optimizing patient journey management, starting from clinical diagnosis to alleviating treatment burdens. The team supports care resource integration to implement treatment adherence programs. Through collaboration with professional consultant management teams, pharmaceutical companies, and other healthcare resource providers, the primary focus is on significant or chronic disease care. PatientsForce provides integrated services related to drug costs, finances, care, and resources, centering on patient journey management to enhance the accessibility and affordability of medical care.

PAP as a Critical Bridge for New Drug Reimbursement

In 2024, PatientsForce executed the "Lessen Patient Burden Plan" (PAP), supporting nearly 60 medication assistance projects across various therapeutic areas, primarily cancer drugs, immune-related diseases, endocrine, and metabolic diseases.

PatientsForce Drug Support Plan Execution by Drug Categories (As of 2024/12/31)

According to the Ministry of Health and Welfare's historical cancer registration report, cancer is the leading cause of death, significantly affecting patients and their families' quality of life. PatientsForce's patient support programs cover various cancer types, with lung and breast cancer being the most common in Taiwan. Many self-funded medications are included in the scope of these services.

PAP serves as a temporary floating bridge for new drugs before they receive insurance reimbursement. Through pharmaceutical company-supported patient drug assistance programs, financially challenged patients can start treatment through physician referrals. In 2024, approximately 16% of PAP project drugs received insurance reimbursement or extended coverage, allowing all or part of the patients to transition to insured drug treatment seamlessly. PatientsForce plays a vital role as a public-private partnership enabler, ensuring collaboration among national health insurance, private insurance, and support programs. This resolves the time lag between supply and demand in the pharmaceutical economy during the self-pay period of new drugs (including medical devices).
 

PatientsForce Drug Distribution by Cancer Type (As of 2024/12/31)

PSP as a Value Service for Special Medication Patient Journeys

In the treatment journey for special medications, case management involves more than follow-up visits. It includes patient event management, encompassing clinical administrative documentation, education for patients and caregivers, cultural differences, barriers to healthcare access such as transportation, and integration of care resources.

The Patient Support Program (PSP) bridges the gap between the "Perfect Protocol" in clinical settings and the "Real World" treatment conditions. In 2024, PatientsForce provided clinical patient assistance services for 17 medications. These included ongoing care before patient follow-up visits, case services accompanying diagnoses, and support for insurance drug applications and tracking management for special patients. Additionally, PatientsForce collaborated with over 40 major medical institutions in Taiwan to provide relevant testing support services, assisting more than 10,000 patients in their treatment journey.

PatientsForce Patient Assistance Outcomes: Measurable Social Impact

To date, PatientsForce has assisted over 60,000 patients, providing a total reduction in drug burden valued at over NT$6 billion. Over the past three years, the number of new patients has increased by an average of 10,000 annually, continuing to grow.

 

PatientsForce actively adopts digital management services, enabling patients to complete consent forms via mobile devices. Medication management interfaces also allow online acknowledgment of medication receipt, improving application process convenience. According to the 2024 digital medical service statistics, over 80% of specific projects utilized digital services, with registered users steadily increasing annually. The most common uses include service inquiries and applications (18%), regular reminders (42%), and support resource inquiries (40%). Beyond improving the efficiency of patient service management, these initiatives also reduce paper usage and journey carbon emissions, achieving environmental value benefits.


 

Professional Partners for International Pharmaceutical Companies' Patient Support Programs

The PatientsForce team collaborates with international pharmaceutical companies. According to the "2024 Pharm Exec Top 50 Companies" published by Pharmaceutical Executive in June 2024, PatientsForce provided various patient solutions for over 20 companies.

This year, PatientsForce’s strategic efforts received the 2024 Visionary ESG Corporate Sustainability Award for Social Innovation (SME category) and the Harvard Business Review Innovation Business Model SME First Prize and ESG Special Award. Additionally, it earned the EcoVadis Badge, ranking in the top 26% globally among professional, scientific, and technical industries. PatientsForce also committed to the Science-Based Target Initiative (SBTi) for SMEs and the 2030 Net-Zero Initiative.

PatientsForce is more than a patient support drug supply chain service. It is advancing toward becoming a socially impactful healthcare resource ecosystem!